Evercore ISI Group maintains Agilon Health at In-Line, raises price target to $105 from $95
Evercore ISI Group kept Agilon Health's rating at In-Line but raised its price target to $105 from $95, suggesting a 9.1% upside from the Nov 4 close of $96.23.
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Decision brief
The 30-second read
Med
01
Why it matters
The rating upgrade may prompt short-term buying, but lacks substantive operational catalysts.
02
Market read
Analyst target raise provides modest trading impetus for AGLN.
03
What to watch
No new earnings or operational data accompany the upgrade.
Relevance 6/10Novelty 6/10Timing: today
Background
Agilon Health is a small-cap healthcare services company; analyst coverage is limited.
Market effects
Sector
May lift sentiment in the healthcare services sector.
Regional
Limited to US small-cap healthcare stocks.
Global
Low
Counterpoint
What could challenge this read
Target raise could be premature if underlying fundamentals remain weak.
Key entities
- analystEvercore ISI Group
Equity research firm issuing the price target raise.
- companyAgilon Health
Subject of the analyst rating change.
